Inversago
AcquiredDeveloping next-generation CB1 blockade therapies for metabolic disease.
Montreal, Canada · Founded 2015 · $112.0M raised
- Headquarters
- Montreal
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
- Website
- inversago.com
- Total Funding
- $112.0M
- Last Round
- $70.0M Series COct 2022
- Rounds
- 3
- Acquisition Date
- Aug 2023
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Inversago Pharma specialized in CB1 receptor blockade therapies for metabolic disorders. Acquired by Novo Nordisk in August 2023.
Summary
Inversago is a Biotech company based in Montreal, Canada, founded in 2015. It has raised $112.0M in total across 3 rounds, most recently a $70.0M Series C round in Oct 2022. Investors include Genesys Capital, Amorchem and New Enterprise Associates.
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
Aug 2023
Sign up to see all 4 events
Funding: Series A through Series C. Amounts, valuations, and investors where available.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/inversago"><img src="https://indexed.vc/api/badge/company/inversago" alt="Inversago on Indexed.vc" width="260" height="76" /></a>